Introduction
The natriuretic peptide ( NP) family is c omprised of four peptide hormones, eac h with a c ommon 1 7 amino ac id ring struc ture. The prec ursor prohormone for eac h is enc oded by a separate gene. The tissue-spec ific distribution and regulation of eac h peptide is different.
Atrial natriuretic peptide ( ANP) and brain natriuretic peptide ( BNP) are similar in their ability to promote natriuresis and diuresis and ac t as vasodilators. These ac tions are c ounterbalanc ed by the vasoc onstric tive and sodium-retaining ac tions of the renin-angiotensinaldosteron system. Both systems help to maintain sodium and fluid volume homeostasis in a healthy c ardio-renal environment. C-type natriuretic peptide and urodilatin ac t predominately as vasodilators. Eac h NP has antimitogenic ac tivity in both the c ardiovasc ular system and other organ systems. This implies that the NPs may modulate growth within the vasc ular wall in disorders suc h as atherosc lerosis, hypetension, and postangioplasty restenosis.
Atrial natriuretic peptide is produc ed mainly in the atria. Inc reased atrial wall tension, reflec ting inc reased intravasc ular volume, is the dominant stimulus for its release. Cleavage of human pro-ANP releases a 9 8 -amino ac id amino-terminal fragment ( NT-proANP) , as well as a 2 8 -amino ac id c arboxy-terminal fragment that is mature ANP whic h is the biologic aly ac tive form of ANP. It has been suggested that a transmembrane serine protease highly expressed in the heart c onverts proANP into ANP and NTproANP. Both fragments c irc ulate in the plasma. Little NP is produc ed by ventric ular tissue in normal adults, but it is present in ventric ular tissue of fetuses and neonates and in hypertrophied ventric les.
The ANP gene is also expressed in the kidney, where alternative proc essing of the prec ursor generates a 3 2 -amino ac id substanc e-urodilatin, one of the fac tors that regulate sodium and water handling in the kidney.
Brain natriuretic peptide was isolated from porc ine brain in 1 9 8 8 . This 3 2 -amino ac id peptide also c ontained a 1 7 -amino ac id ring ( Figure 1 ) . The name brain natriuretic peptide quic kly bec ame something of a misnomer when it was disc overed that the highest level of BNP was in the ventric ular myoc ardium. Human proBNP c ontain 1 0 8 amino ac ids; proc essing releases a mature 3 2 -amino ac id molec ule of BNP and an amino terminal fragment NTproBNP ( 1 -7 6 amino ac ids sequenc e) .
A third peptide, C-type natriuretic peptide ( CNP) , a parac rine hormone with high c onc entrations in the vasc ular endothelium, belongs to this family as well. There are two forms of CNP c onsisting of either 5 3 or 2 2 amino ac ids; both lac k an amino ac id tail at the c arboxy terminal.
Another member of the natriuretic peptide family is urodilatin whic h is loc alized in the kidneys and sec reted into urine. It is a parac rine fac tor involved in the loc al regulation of the body fluid volume and water-elec trolyte exc retion by regulating water and sodium reabsorption. Urodilatin is a differentially proc essed form of prec ursor proANP. ANP and CNP are highly c onserved ac ross spec ies, whereas BNP shows spec ies spec ific ity.
The natriuretic peptides are ligands for three different natriuretic peptide rec eptors ( NPR) , that are named A, B and C, with designation not c orresponding to their relative affinities for ANP, BNP and CNP. All three rec eptors are widely distributed in target tissues and have been loc alized in the kidney, heart, vasc ular endothelium, adrenals, and throughout the c entral nervous system. The NPR are transmembrane proteins, members of the rec eptor guanyl c yc lase family. The c learanc e of NPs from the c irc ulation oc c urs via two mec hanisms; first, via NPR-C rec eptormediated endoc ytosis, followed by lysosomal degradation; sec ond, via degradation by the zinc -c ontaining enzyme, neutral endopeptidase, a non-spec ific membrane-bound enzyme present in the kidney and vasc ular beds that c leaves NPs and opens the ring struc ture, thus inac tivating the peptides.
H eart failure
Heart failure ( HF) is a multisystem disorder whic h is c harac terized by abnormalities of c ardiac , skeletal musc le, and renal func tion; stimulation of the sympathetic nervous system; and a c omplex pattern of neurohormonal c hanges.
HF is the major c ause of c ardiovasc ular morbidity and mortality and is one of the main c auses of hospitalization in industrial c ountries. Currently, the prevalenc e of symptomatic HF in the general European population ranges from 0 .4 to 2 .0 perc ent. To provide c ost-effec tive treatment for these patients, rapid and ac c urate differentiation of c ongestive heart failure from other c auses of dyspnoea must be ac c omplished. However, HF is often diffic ult to diagnose in the emergenc y department or urgent c are setting. The symptoms may be nonspec ific , and physic al findings are not sensitive enough to use as a basis for an ac c urate diagnosis. Although ec hoc ardiography is c onsidered the gold standard for the detec tion of left ventric ular dysfunc tion, it is expensive. Is not always easily ac c essible, and may not always reflec t an ac ute c ondition. Misdiagnosis c an be life-threatening, bec ause treatments for c ongestive heart failure are hazardous to patients with other c onditions, suc h as c hronic obstruc tive pulmonary disease, that have the same primary symptoms at presentation.
Early diagnosis and treatment of HF are important fac tors in reduc ing morbidity and mortality assoc iated with the disease.
Diagnostic and prognostic use of AN P and BN P
NP determination is a useful addition to the standard c linic al investigation of patient with ventric ular dysfunction. During several years muc h work has demonstrated that NPs are the bioc hemic al markers of c hoic e for diagnosing and risk stratific ation of patients with HF. In side-by-side c omparison, NPs were superior to other neurohormones, suc h as c atec holamines, renin, angiotensin and aldosterone. The NP assays disc riminated very well between c ontrols and patients with end-stage HF. BNP measurement appears to be ac c urate for diagnosing HF in emergenc y department patients who present with ac ute dyspnoea. Inc reased NP plasma c onc entrations are, however, also frequently found in asymptomatic patients with left ventric ular dysfunc tion. Therefore, these peptides have also been suggested as potentially useful early HF markers.
BNP is elevated in post myoc ardial infarc t patients with impaired left ventric ular func tion and BNP appears to be superior to ANP for identifying left ventric ular systolic dysfunc tion. The very high negative predic tive value of BNP in the detec tion of these diseases gives the best insight into how this test might be used c linic ally.
NP may be even more useful as prognostic indic ators than as diagnostic markers. Elevated plasma levels of BNP have been suggested as an independent predic tor of the severity of c ongestive HF and of mortality in patients with c hronic HF.
The value of NPs has already been rec ognized by their inc lusion in the rec ent European guidelines for the diagnosis of c hronic HF.
Measurement of natriuretic peptides
The developing of a sensitive, prec ise, and ac c urate method for NPs measurement has been diffic ult bec ause of the struc tural, metabolic , and physiologic al c harac teristic s of these proteins. Therefore, several important points should be taken into ac c ount when disc ussing the pathophysiologic al relevanc e of partic ular NP assay:
• The goal should be to assess the ac tivity of a spec ific hormone system; therefore, only the biologic ally ac tive substanc es of this system should be assayed. • Although ANP and BNP bind to same spec ific rec eptor, they have different types of metabolism and biologic al ac tivity, and their produc tion and sec retion may be regulated differently in humans.
• ANP and BNP are stored in granules in form of proNP, whic h are split into an ac tive form of ANP and BNP and their N-terminal fragment. Several studies have demonstrated that N-terminal proANP and N-terminal BNP have also some biologic al ac tivity. However, these molec ules exhibit ( at least in part) different biologic al properties as well as different mec hanism of ac tion with respec t to the ANP/BNP system.
• NPs are degraded both in vivo and in vitro by several proteases. EDTA and protease inhibitors ( aprotinin) are generally added to whole blood samples to inhibit this degradation. Some rec ent studies have suggested that the use of protease inhibitors may be not nec essary, at least for BNP and proANP.
The determination of the biologic ally ac tive form of NPs ( ANP and BNP) is generally performed by means of c ompetitive immunoassays, suc h as RIA or EIA; rec ently some nonc ompetitive immunoassays have been developed. The methods of this sec ond generation are two-site ( sandwic h) immunometric assays, using two spec ific monoc lonal antibodies or antisera prepared against two steric ally remote epitopes of the ANP and BNP peptide c hain.
Nonc ompetitive assays are generally more prec ise and sensitive than their respec tive c ompetitive assays and are not signific antly affec ted by nonspec ific interferenc e. These fac ts suggest that non-c ompetitive immunoassays for ANP and BNP may be more suitable for c linic al routine than c ompetitive assays.
Theoretic ally, developing an immunoassay for N-terminal peptide fragments of proANP and proBNP should be easier, bec ause these peptides have higher plasma c onc entrations. However, these immunoassays may also be affec ted by several analytic al problems, mainly c onc erning the assay spec ific ity. Bec ause there is no a general c onsensus on the best method for NPs assay, at the present time eac h laboratory must c hoose the methods and the peptides to measure that meet its own c linic al requirements as well as to other issues, suc h as stability of both analytes and materials, ease of measurement, and c osts.
Preanalytical factors
ANP has very short half-life time ( 3 minutes) and is poorly stable in vitro and thus appears suitable only for point-ofc are measurement under routine c onditions. By c ontrast, BNP ( 2 0 min.) , NT-proANP ( 6 0 min.) , and NT-proBNP ( 6 0 -1 2 0 min.) are suffic iently stable in EDTA-c ontaining plastic tubes to be sent to the laboratory without spec ial c are. When handling NP, glassware should be avoided or must be c arefully silic onized to avoid adsorption of NP to the wall. The larger N-terminal prohormone fragments are more stable and have a longer biologic al half-life and requirements for blood sampling are less c ritic al. They are also less sensitive to the rapid fluc tuations c aused by shortterm stimuli of sec retion, suc h as c hange in body posture, exerc ise, or ac ute volume load.
So far, preanalytic influenc es on NP c onc entrations are not c ompletely c lear. Therefore, blood sampling should be performed under standardized c onditions. It has been reported by some investigators that BNP values are higher in healthy women than in healthy men, and that there is a positive relationship between BNP values and age.
Conclusions
Studies of the NP family have inc reased our understanding of blood-volume regulation and blood-pressure c ontrol. The natriuretic peptides defend against exc ess salt and water retention, inhibit the produc tion and ac tion of vasoc onstrictor peptides, promote vasc ular relaxation, and inhibit sympathetic outflow. These ac tions lead to a reduc tion in blood pressure that is most apparent in states of volume exc ess. NPs may be most useful c linic ally as a rule-out test due to c onsistent and very high negative predic tive values.
The value of NP assays has already been rec ognized by their inc lusion in the rec ent European guidelines for the diagnosis of c hronic HF. At present time there is no c onsensus on the best method for NP assay, although non-c ompetitive immunoassays may be more suitable for c linic al routine than c ompetitive assays. Therefore, eac h laboratory must c hoose the methods and the peptides to assay that meet its own c linic al requirements.
